Evidence map›Paper›PMID 37558496›Full record

Observational studyJournal of atherosclerosis and thrombosis2024

Validation of the Usefulness of the Diameter Reduction, Spiral Shape, Flow Impairment, or Adverse Morphology Classification System in Real-World Clinical Practice.

Takehiro Yamada, Takahiro Tokuda, Naoki Yoshioka, Akio Koyama, Ryusuke Nishikawa, Kiyotaka Shimamura, Takuya Tsuruoka, Hiroki Mitsuoka, Takuma Aoyama

Abstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of atherosclerosis and thrombosis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Takehiro YamadaDivision of Cardiology, Central Japan International Medical Center.
Takahiro TokudaDivision of Cardiology, Nagoya Heart Center.
Naoki YoshiokaDivision of Cardiology, Ogaki Municipal Hospital.
Akio KoyamaDivision of Vascular surgery, Toyota Memorial Hospital.
Ryusuke NishikawaDivision of Cardiology, Kyoto University Hospital.
Kiyotaka ShimamuraDivision of Cardiology, Shizuoka General Hospital.
Takuya TsuruokaDivision of Vascular surgery, Ichinomiya Municipal Hospital.
Hiroki MitsuokaDivision of Vascular surgery, Aichi Medical University Hospital.
Takuma AoyamaDivision of Cardiology, Central Japan International Medical Center.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe accuracy of the DISFORM (diameter reduction, spiral shape, flow impairment, or adverse morphology) classification system has not been validated.

methodsThis retrospective multicenter observational study enrolled 288 consecutive patients with lower extremity artery disease who underwent endovascular therapy with drug-coated balloons for femoropopliteal lesions between January 2018 and December 2021. Patients were classified into DISFORM I-IV groups. Primary patency (PP) and freedom from clinically driven target lesion revascularization (CD-TLR) at 12 months, and recurrence predictors at 12 months were investigated.

resultsIn total, 183, 66, 11, and 28 patients were classified into DISFORM I, II, III, and IV groups, respectively. In the DISFORM I, II, III, and IV groups, the PP rates were 75.3%, 91.1%, 87.5%, and 50.0%, respectively, and freedom from CD-TLR rates were 86.0%, 91.6%, 88.9%, and 76.7%, respectively, at 12 months. In the DISFORM I-III and IV groups, the PP rates were 79.4% and 50.0%, respectively, and freedom from CD-TLR rates were 87.5% and 76.7%, respectively, at 12 months. Multivariate analysis showed that chronic limb-threatening ischemia, DISFORM IV, and Lutonix™ use were independent predictors of PP loss at 12 months.

conclusionDISFORM IV had a lower PP rate than DISFORM I-III in midterm phase.

Indexed as

Angioplasty, BalloonCardiovascular AgentsPeripheral Arterial DiseaseCoated Materials, BiocompatibleFemoral ArteryHumansIschemiaPopliteal ArteryTime FactorsTreatment OutcomeVascular PatencyCardiovascular AgentsCoated Materials, BiocompatibleDISFORM classification systemDrug-coated balloonEndovascular therapyLower extremity artery diseaseRestenosis

Identifiers

PMID37558496
PMCPMC10857836

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.